References
- Schnerch D, Lausch E, Becker H, et al. Up-regulation of RUNX2 in acute myeloid leukemia in a patient with an inherent RUNX2 haploinsufficiency and cleidocranial dysplasia. Leuk Lymphoma. 2014;55:1930–1932.
- Callea M, Fattori F, Yavuz I, Bertini E. A new phenotypic variant in cleidocranial dysplasia (CCD) associated with mutation c.391C > T of the RUNX2 gene. BMJ Case Rep. 2012;2012. doi: 10.1136/bcr-12-2011-5422.
- Lee KE, Seymen F, Ko J, et al. RUNX2 mutations in cleidocranial dysplasia. Genet Mol Res. 2013;12:4567–4574.
- Gardham A, Forsythe E, Goulden N. One in 10 million: a case of cleidocranial dysplasia and acute lymphoblastic leukaemia–more than just a coincidence? Clin Dysmorphol. 2012;21:170–171.
- Alpar D, Wren D, Ermini L, et al. Clonal origins of ETV6-RUNX1 acute lymphoblastic leukemia: studies in monozygotic twins. Leukemia. 2015;29:839–846.
- Blyth K1, Vaillant F, Jenkins A, et al. RUNX2 in normal tissues and cancer cells: a developing story. Blood Cells Mol Dis. 2010;45:117–123.
- Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114:5352–5361.
- Adya N, Stacy T, Speck NA, et al. The leukemic protein core binding factor beta- smotth- muscle myosin sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol. 1998;18:7432–7443.
- Quack I, Vonderstrass B, Stock M, et al. Mutation analysis of core binding factor A1 in patients with cleido-cranial dysplasia. Am J Hum Genet. 1999;65:1268–1278.
- Zhou G, Chen Y, Zhou L, et al. CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Hum Mol Genet. 1999;8:2311–2316.
- Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29:1364–1372.